Abhra Banerji

In a blow to human judgement, "computer-driven quants, which pick shares based on factors like momentum and size, have been the only hedge fund category to buy additional stock in 2016," Bloomberg reported, citing data from Credit Suisse Group AG. According to Credit Suisse Global Head of Risk...

Biotech IPOs have long been alluring for investors because of how difficult it is to resist buying into the opportunity for a major biotech breakthrough. Shareholders of the company that finally cures cancer will likely all be instant millionaires, so why not take a stake in the next hot biotech...